-
Mashup Score: 3Episode 386: ASCO GU 2025 - STOPCAP Meta-Analysis | GU Oncology Now - 3 month(s) ago
Dr. Tanya Dorff joins The Uromigos to discuss results of the STOPCAP trial from ASCO GU 2025, along with new data from TALAPRO-2.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7The Uromigos Episode 385: ASCO GU 2025 - TALAPRO-2 | GU Oncology Now - 3 month(s) ago
Dr. Neeraj Aggarwal joins The Uromigos for an in-depth look at important data from TALAPRO-2.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Review today's #TALAPRO-2 data with @neerajaiims and The Uromigos in their latest @ASCO #GU25 episode: https://t.co/UylyPgQ0sT
-
-
Mashup Score: 0TALAPRO-2: Final OS After First-Line Treatment for Patients With mCRPC | GU Oncology Now - 3 month(s) ago
Tala/enza demonstrated improvement in OS compared with enza alone as 1L treatment in patients with mCRPC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🚨 The latest data on the TALAPRO-2 study presented at @ASCO #GU25 by @neerajaiims has demonstrated signifcant improvement in OS for patients with #mCRPC through the use of #talazoparib with #enzalutamide: https://t.co/aX0wZslpCW
-
-
Mashup Score: 3PSMAfore Data Highlight ctDNA as a Key Predictor of Treatment Outcomes in mCRPC | GU Oncology Now - 3 month(s) ago
A new analysis of the PSMAfore trial presented at ASCO GU 2025 has assessed the link between baseline and cycle 2 day 1 (C2D1) ctDNA fraction.
Source: guoncologynow.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 Just presented at @ASCO #GU25: A new analysis of the #PSMAfore trial has assessed the link between baseline and cycle 2 day 1 #ctDNA fraction. 🔎 See which one may be more strongly associated with rPFS and OS: https://t.co/wLL6mOmOmV
-
-
Mashup Score: 1Enhanced Metastatic Detection With PSMA PET: Implications for Prognostic Classification in mCSPC | GU Oncology Now - 3 month(s) ago
A single-center study presented at ASCO GU 2025 compared patients with metastatic mCSPC staged with PSMA PET after curative therapy or de novo metastatic disease.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
👉 A new study presented at @ASCO #GU25 compared patients with metastatic #mCSPC staged with PSMA PET after curative therapy or de novo metastatic disease. 📈 When applied to volume curves, #PSMA PET appears to provide prognostic value: https://t.co/uW84BBtF9d
-
-
Mashup Score: 1Comparing ARPIs and Docetaxel in mHSPC: Insights From the STOPCAP IPD Meta-Analysis | GU Oncology Now - 3 month(s) ago
A meta-analysis of the STOPCAP trial from ASCO GU 2025 sought to determine which patients with mHSPC may benefit more from treatment using ARPIs over docetaxel with ADT doublet.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔊 A meta-analysis of the #STOPCAP trial presented at @ASCO #GU25 determined which patients with mHSPC may benefit more from ARPIs over docetaxel doublets. 🔎 ARPI & docetaxel doublets seem to be similarly effective in high-volume, synchronous disease: https://t.co/mEgjZpEex7
-
-
Mashup Score: 1Radiotherapy vs Radical Prostatectomy for High-Risk Prostate Cancer | GU Oncology Now - 3 month(s) ago
Radiotherapy may reduce distant metastasis risk in high-risk prostate cancer compared to surgery, according to new study.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔬 A new analysis suggests that radiotherapy-based strategies may result in a lower risk of distant metastasis in patients with high-risk #prostate cancer. 👉 Learn more about the study just presented at @ASCO #GU25: https://t.co/xVe2md8YJg
-
-
Mashup Score: 5ASCO GU Research to Watch: Prostate Cancer | GU Oncology Now - 3 month(s) ago
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on TALAPRO-2, studies on oligometastatic disease, and more.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
☀️ Get ready for day 1 of @ASCO #GU25 with the @TwoOncDocs as they review the top #prostatecancer research to keep an eye on today, including TALAPRO-2 and more 📺 : https://t.co/dlEqGlTmUm https://t.co/xUaWop2bjw
-
-
Mashup Score: 10ASCO GU Preview: Prostate, Bladder, and Kidney Cancer Research to Monitor | GU Oncology Now - 3 month(s) ago
Dr. Ciuro previews the potential practice-changing research in prostate, bladder, and kidney cancers from ASCO GU 2025.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Get ready for the start of @ASCO #GU25 tomorrow by learning about some of the top research to look out for with @jordanciuro! 📺 Dr. Ciuro highlights research in #prostatecancer treatment advancements, emerging therapies in #bladdercancer, and more: https://t.co/bNE34HDmmU
-
-
Mashup Score: 1Robotic Surgery, Multidisciplinary Care for RCC | GU Oncology Now - 3 month(s) ago
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Source: guoncologynow.comCategories: General Medicine News, UrologyTweet-
⭐ At @dsui_miami_uro's Urology On The Beach meeting, we spoke with @drjkaouk of @ClevelandClinic on how a multidisciplinary team should be integrated into the management of RCC. 📺 He also discusses the benefits of robotic platforms for nephrectomy: https://t.co/v5ds9LTfc5 https://t.co/EMhwmZ1E9O
-
🔊 Listen to the new @Uromigos episode with @TDorffOnc on results of the #STOPCAP meta-analysis from @ASCO #GU25: https://t.co/fdwj8JLSCe